H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the top most undervalued biotech stocks to buy now. On August 6, H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $75 from $72, keeping a Buy rating on the shares.

The rating update came after Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported its fiscal Q2 2025 results.

The analyst told investors in a research note that Halozyme Therapeutics, Inc. (NASDAQ:HALO) raised its fiscal 2025 guidance for the third time this year following another quarter of solid results.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported its fiscal Q2 2025 results on August 5, with total revenue increasing 41% year-over-year to $326 million and royalty revenue growing 65% year-over-year to $206 million.

Net income for the quarter rose 77% year-over-year to $165 million, while adjusted EBITDA increased 65^ year-over-year to $226 million.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology.

They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.

While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.